Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema. The company also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone678-270-3631
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$340,000.00
Profitability
Miscellaneous
Employees34
OptionableOptionable
Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions
What is Clearside Biomedical's stock symbol?
Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."
How were Clearside Biomedical's earnings last quarter?
Clearside Biomedical Inc (NASDAQ:CLSD) announced its quarterly earnings results on Wednesday, August, 8th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.07. View Clearside Biomedical's Earnings History.
When is Clearside Biomedical's next earnings date?
What price target have analysts set for CLSD?
8 brokerages have issued 12 month price targets for Clearside Biomedical's shares. Their predictions range from $4.00 to $29.00. On average, they anticipate Clearside Biomedical's stock price to reach $12.7143 in the next twelve months. This suggests a possible upside of 704.7% from the stock's current price. View Analyst Price Targets for Clearside Biomedical.
What is the consensus analysts' recommendation for Clearside Biomedical?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clearside Biomedical.
Has Clearside Biomedical been receiving favorable news coverage?
Headlines about CLSD stock have been trending positive this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Clearside Biomedical earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the near term.
Are investors shorting Clearside Biomedical?
Clearside Biomedical saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,120,474 shares, an increase of 44.2% from the January 15th total of 776,819 shares. Based on an average trading volume of 261,264 shares, the short-interest ratio is currently 4.3 days. Approximately 4.7% of the company's shares are short sold. View Clearside Biomedical's Current Options Chain.
Who are some of Clearside Biomedical's key competitors?
Some companies that are related to Clearside Biomedical include CELYAD SA/ADR (CYAD), Aeglea Bio Therapeutics (AGLE), Newron Pharmaceuticals (NWPHF), TAIWAN LIPOSOME/S (TLC), Aptinyx (APTX), Recro Pharma (REPH), Spero Therapeutics (SPRO), AcelRx Pharmaceuticals (ACRX), REDHILL BIOPHAR/S (RDHL), Protagonist Therapeutics (PTGX), Spring Bank Pharmaceuticals (SBPH), Molecular Templates (MTEM), Aquestive Therapeutics (AQST), ProMetic Life Sciences (PFSCF) and Zafgen (ZFGN).
Who are Clearside Biomedical's key executives?
Clearside Biomedical's management team includes the folowing people:
- Mr. Daniel H. White, Founder, Pres, CEO & Director (Age 52)
- Mr. Charles A. Deignan, CFO & Sec. (Age 55)
- Mr. Stephen C. Kilmer, Investor Relations Officer (Age 53)
- Mr. Leslie B. Zacks, Gen. Counsel & Chief Compliance Officer (Age 50)
- Mr. Rick McElheny, VP of Corp. Devel.
When did Clearside Biomedical IPO?
(CLSD) raised $50 million in an initial public offering (IPO) on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.
Who are Clearside Biomedical's major shareholders?
Clearside Biomedical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sphera Funds Management LTD. (3.70%), Northpointe Capital LLC (1.76%), Millennium Management LLC (1.71%), Geode Capital Management LLC (0.95%), Two Sigma Investments LP (0.65%) and Tekla Capital Management LLC (0.52%). Company insiders that own Clearside Biomedical stock include Charles A Deignan, Christy L Shaffer, Clay Thorp, Daniel H White and Gerald D Cagle. View Institutional Ownership Trends for Clearside Biomedical.
Which institutional investors are selling Clearside Biomedical stock?
Which institutional investors are buying Clearside Biomedical stock?
CLSD stock was purchased by a variety of institutional investors in the last quarter, including Fosun International Ltd, Two Sigma Investments LP, Tekla Capital Management LLC, Virtu Financial LLC, SG Americas Securities LLC, Sphera Funds Management LTD., Bank of New York Mellon Corp and Alambic Investment Management L.P.. Company insiders that have bought Clearside Biomedical stock in the last two years include Charles A Deignan, Christy L Shaffer, Clay Thorp, Daniel H White and Gerald D Cagle. View Insider Buying and Selling for Clearside Biomedical.
How do I buy shares of Clearside Biomedical?
Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clearside Biomedical's stock price today?
One share of CLSD stock can currently be purchased for approximately $1.58.
How big of a company is Clearside Biomedical?
Clearside Biomedical has a market capitalization of $50.60 million and generates $340,000.00 in revenue each year. The company earns $-58,970,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Clearside Biomedical employs 34 workers across the globe.
What is Clearside Biomedical's official website?
How can I contact Clearside Biomedical?
Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]
MarketBeat Community Rating for Clearside Biomedical (NASDAQ CLSD)
MarketBeat's community ratings are surveys of what our community members think about Clearside Biomedical and other stocks. Vote "Outperform" if you believe CLSD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSD will underperform the S&P 500 over the long term. You may vote once every thirty days.
